GCG and obesity disorder: Given the surge in GLP-1 agonist use in treatment of diabetes and obesity, further prospective studies are needed to investigate the impact of GLP-1 agonists on RGC rates based on therapeutic indication, which can ultimately help guide endoscopy-related and peri-procedure recommendations.